reason report
fear unwarr solid result guid posit set-up
event
bottom line morn alexion announc ep
consensu estim driven
stronger sale across product reduc lower tax
rate investor increasingli worri headwind
soliri slowdown revenu growth quarter
strong result alter neg sentiment alexion
stock alexion report total pro forma revenu
consensu forecast
soliri revenu consensu
estim soliri revenu increas yoy
increas qoq full-year revenu increas
attribut volum product also overcam structur
headwind clinic trial enrol
strensiq kanuma beat consensu estim
respect total non-gaap expens lower
consensu higher estim driven
lower spend despit increas sg quarter alexion
tax rate lower compar consensu
expect report non-gaap ep
consensu estim
manag guidanc conserv compani histori
beat rais estim believ stock react
posit strength quarter ahead two signific catalyst
phase pnh soliri phase nmo
pnh soliri nmo phase trial confirm
data alexion provid increment key pipelin regulatori
updat quarterli report howev manag re-affirmed
execut two import catalyst year
pnh studi still anticip data
soliri nmo studi still anticip data
initi guidanc similar segment last year product sale
guid consensu
estim revenu guidanc
includ unfavor soliri revenu impact
trial off-set partial fx benefit soliri revenu
guid metabol revenu guid
guidanc rang recent
consensu estim soliri forecast
top end rang non-gaap guid
non-gaap sg guid lead
guid oper margin anticip alexon
neg impact new us tax law guid rate
compar consensu result non-gaap ep
guidanc consensu
pleas refer page import disclosur price chart analyst certif
initi estim mid-point main chang forecast
incorpor higher tax rate guidanc
topic compani upcom confer
call et like
commentari expect uptak soliri newly-approv
mg popul develop updat soliri neuromyel
optica nmo time data releas variou
popul also discuss subcutan
version phase trial plan initi
also expect hear progress report compani restructur
announc
sale non-gaap
share count period dilut
guidanc
